Quantitative approaches provide new perspective on development of antibiotic resistance

Nov. 28, 2013 — Using quantitative models of bacterial growth, a team of UC San Diego biophysicists has discovered the bizarre way by which antibiotic resistance allows bacteria to multiply in the presence of antibiotics, a growing health problem in hospitals and nursing homes across the United States.

Two months ago, the Centers for Disease Control and Prevention issued a sobering report estimating that antibiotic-resistant bacteria last year caused more than two million illnesses and approximately 23,000 deaths in the United States. Treating these infections, the report said, added $20 billion last year to our already overburdened health care system.

Many approaches are now being employed by public health officials to limit the spread of antibiotic resistance in bacteria -- such as limiting the use of antibiotics in livestock, controlling prescriptions of antibiotics and developing new drugs against bacteria already resistant to conventional drug treatments. But understanding how bacteria grow and evolve drug resistance could also help stop its spread by allowing scientists to target the process of evolution itself.

"Understanding how bacteria harboring antibiotic resistance grow in the presence of antibiotics is critical for predicting the spread and evolution of drug resistance," the UC San Diego scientists say in an article published in the November 29 issue of the journal Science.

In their study, the researchers found that the expression of antibiotic resistance genes in strains of the model bacterium E. coli depends on a complex relationship between the bacterial colony's growth status and the effectiveness of the resistance mechanism.

"In the course of developing complete resistance to a drug, a strain of bacteria often first acquires a mechanism with very limited efficacy," says Terry Hwa, a professor of physics and biology who headed the research effort. "While much effort has been spent elucidating individually how a drug inhibits bacterial growth and how a resistance mechanism neutralizes the action of a drug, little is known previously about how the two play off of each other during the critical phase where drug resistance evolves towards full strength."

According to Hwa, the interaction between drug and drug-resistance is complex because the degree of drug resistance expressed in a bacterium depends on its state of growth, which in turn depends on the efficacy of drug, with the latter depending on the expression of drug resistance itself. For a class of common drugs, the researchers realized that this chain of circular relations acted effectively to promote the efficacy of drug resistance for an intermediate range of drug doses.

The use of predictive quantitative models was instrumental in guiding the researchers to formulate critical experiments to dissect this complexity. In their experiments, E. coli cells possessing varying degrees of resistance to an antibiotic were grown in carefully controlled environments kept at different drug doses in "microfluidic" devices -- which permitted the researchers to manipulate tiny amounts of fluid and allowed them to continuously observe the individual cells. Hwa and his team found a range of drug doses for which genetically identical bacterial cells exhibited drastically different behaviors: while a substantial fraction of cells stopped growing despite carrying the resistance gene, other cells continued to grow at a high rate. This phenomenon, called "growth bistability," occurred as quantitatively predicted by the researchers' mathematical models, in terms of both the dependence on the drug dose, which is set by the environment, and on the degree of drug resistance a strain possesses, which is set by the genetic makeup of the strain and is subject to change during evolution.

"Exposing this behavior generates insight into the evolution of drug resistance," says Hwa. "With this model we can chart how resistance is picked up and evaluate quantitatively the efficacy of a drug." However, this model has only been established for one class of drugs and one class of drug-resistance mechanisms. Hwa believes it is important to establish such predictive models for all the common drugs in pathogenic bacterial species.

"My hope," he adds, "is to get the message out to drug companies and hospitals that there is an informative, quantitative way to look at the action of a drug on bacteria and at the consequences of using a drug on bacteria as they try to pick up resistance, and that this approach can be incorporated in both the design and evaluation of drug efficacy in clinically relevant settings."

Hwa says the principle of interaction between drug and drug-resistance is important to understand not only for the evolution of antibiotics, but also for the emergence of drug resistance in other diseases. A prominent example is the rapid emergence of cancer lines resistant to drug treatment, which underlies most failures in cancer drug therapies. While there are obviously numerous differences between the evolution of drug resistance in bacteria and in cancer, Hwa noted that the connection between the two was sufficient to motivate the Physical Science-Oncology program of the National Cancer Institute to co-sponsor this study.

View the original article here

By the genetic effects of sharing new approaches subtypes cancers

Develop a fact that tumors are almost never confounded the shared scientific efforts with exactly the same genetic mutation, cancer types targeted more predicaments, effective treatment. Paper published in the online edition of nature methods and advanced 9/15 California College San Diego (Moores Comprehensive Cancer Center home ） of researcher presents a new approach called network-based stratified (NBS) to identify subtypes of cancer due to shared genetic networks and systems of these mutations, not peculiar mutation in each patient.

View the original article here

To protect from cancer cell death 2 approaches

Summary:

There are different security applications without creating a most cancers, and avoid getting under the cell management pressure and to protect them from split two. Until now, these safety scientists believed, wheeled technology independently from each other. Cancer is a scary term. Passed from cancer, most people away very got sick and tired of someone we know. In most cases, affect cancer aged.

The main idea:

Many disease-related groups and all cells need actually cancer. Cell is including the human body, living thing, a very small unit. Measurement of cells in each person's body is not possible.

Recurring cancer cells most of what happens. Usually develop the cell splits, and know the increases stop. Also take the time to die. Split opposed the regular cells, cancer cells only increased control when they are supposed not to die is.

Cancer cells are usually group together the heap of forms of cancer or. You can eliminate the growth of normal cells around the tumor growth and makes masses of malignant tumor cells of malignant melanoma, damage healthy cells in the body. People very sick can be.

The cause of the cancer:

Development eventually, recalcitrant, most cancer is the result of the tissue doesn't die. Regular organizational body, run AutoArchive path loss of growth, Division, and life. Called and apoptosis of cell loss of life of the design, this process of seizure if starts melanoma malignant tumors to form. Whereas a regular organization, malignant tumors of melanoma have caused loss of life program increase instead, split. This happens mass irregular organization, out of control development.

Cancer treatment:

Most cancer treatment is determined by the stage of the additions to the position of a type of malignant tumor of malignant melanoma, melanoma, how much it spread malignancy, age, health, and personal. Malignant tumor of malignant melanoma, one strategy no patients receive modern and various treatment often. The treatment usually following categories classified: surgery or x-ray, light therapy, immunotherapy, hormone therapy, gene therapy.

May change apoptosis fairly malignant melanoma, malignant tumor tissue apoptosis route is actually probably capacity traditional treatment is often most cancer organizations to view the mediation level by non-effective capacity. Therefore, the main purpose of study of malignant melanoma, malignant tumors is to succeed this route to reactivate apoptosis, use system defects in the development of new strategies for cancer cell growth and migration hand.

Autophagy is broken, unwanted proteins and organ clearance mobile phone degradation pathway. Recycling the elements in these cells also helps to keep constancy and practicality during metabolic stress time as a power source. In the matter of apoptosis in tumor tissue can Autophagy extended success. Paradoxically, is associated with tumor of Autophagy issue improvement and behind this procedure is not established. Shows the description of safety features to limit the swelling and the latest evidence of Autophagy tumor necrosis and reduce genome damage in reaction to the pressure of the tumor tissue metabolism.

Forgiveness is a great word to anyone with cancer the most. In other words, body is missing from all the symptoms most cancers. Medical treatment, chemotherapy or x-ray, treatment after doctors [would evaluate whether cancer is still in. In the absence of symptoms of cancer, remission is a child.

When you go to the Medical Center in cancer therapy for most of all children is the purpose of forgiveness. From phototherapy add this awhile back, you must to keep cancer organizations shows.

Conclusion:

Overall the techniques described above, recognition of target molecules play an important role in most cancer drug resistance means a challenge to most cancer analysis, self-defeating. Now standard concept of quiet apoptosis activation in parallel, can be a valuable treatment of cancer tissue modulation of Autophagy's most sensitive to modern concepts. In need of answers to some United Nations concerns further recognizes the interconnection between the steps work yet.